Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817674 · ClinicalTrials.gov registry record
Sleep Disturbances as a Non-traditional Risk Factor in CKD-Actigraphy
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 353
- Enrollment target
NCT00817674: Completed study, sponsored by University of Chicago.
NCT00817674 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 353 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00817674 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 353 participants
- Enrollment target
Study Summary
To test if usual at home night time sleep duration as measured with activity monitors and questionnaires will predict changes in kidney function as measured by kidney filtration rate and of cardiovascular function as measured by C-reactive protein in the blood. The study will explore the role of decreased sleep time or decreased sleep quality as a non-traditional risk factor for the progression of CKD and for the development of cardiovascular disease in CKD.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-10 |
What the finished NCT00817674 record still lists
NCT00817674 is an observational study that tracks outcomes without assigning an intervention. The registered 353 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00817674 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00817674 about?
NCT00817674 is a clinical study titled "Sleep Disturbances as a Non-traditional Risk Factor in CKD-Actigraphy". To test if usual at home night time sleep duration as measured with activity monitors and questionnaires will predict changes in kidney function as measured by kidney filtration rate and of cardiovascular function as measured by C-reactive protein in the blood. The study will explore the role of dec...
What is the current status of trial NCT00817674?
This trial is currently completed. The enrollment target is 353 participants. The study started on 2007-11. Estimated completion is 2010-10.
Who is sponsoring clinical trial NCT00817674?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05548296 · 353 participants · Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- NCT05884775 · 353 participants · NA
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia